Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ornstein, D. L.
Right arrow Articles by Rigas, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ornstein, D. L.
Right arrow Articles by Rigas, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:S35-S40, 1999
© 1999 European Society for Medical Oncology

Review

Docetaxel (Taxotere®) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer*

D. L. Ornstein, A. M. Nervi and J. R. Rigas

The Norris Cotton Cancer Center, the Sections of Hematology/Oncology, Department of Medicine, Dartmouth Hitchcock Medical Center Lebanon, NH, and Dartmouth Medical School, Hanover, NH, USA

Correspondence to:, J. R. Rigas, MD, Director, Thoracic Oncology Program, One Medical Center Drive, Lebanon, NH 03756-0001, USA, E-mail: james.r.rigas{at}dartmouth.edu

Docetaxel is one of the most active single agents for the treatment of non-small-cell lung cancer. Given the preclinical indications for synergy and the lack of cross-resistance with other active agents in this disease, clinical trials of docetaxel combinations have been undertaken. Phase I and II clinical trials of docetaxel in combination with cisplatin, carboplatin, gemcitabine, vinorelbine, or thoracic radiation for patients with non-small-cell lung cancer were reviewed. The endpoint for phase I trials was to define the phase II doses for the docetaxel combinations where overall response rates, median and one year survival were the endpoints. Five phase I–II studies of docetaxel and cisplatin have reported response rates ranging from 21% to 48%. Median survival times ranged from 8 to 13 months, and one-year survivals from 32% to 58%. Combining docetaxel with vinorelbine resulted in a 37% response rate and a median survival of 9.4 months. Docetaxel in combination with gemcitabine produced a response rate of 53%. The adverse events of these combinations were manageable. Responses have also been reported in studies of docetaxel administered with carboplatin or thoracic radiation therapy. Combinations of docetaxel with platinum, vinorelbine, gemcitabine, and radiation were active in non-small-cell lung cancer with acceptable adverse effects. Phase HI trials are currently in progress to further define the role of docetaxel combinations in the first-line treatment of this disease.

lung cancer, radiotherapy, Taxotere

*These studies were presented in part on 30 May 1998 at the 3rd International Congress on Cancer, Venezia, Italy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
K. V. Mattson, R. P. Abratt, G. ten Velde, and K. Krofta
Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study
Ann. Onc., January 1, 2003; 14(1): 116 - 122.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.